152 related articles for article (PubMed ID: 6215981)
1. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
Isaacs JT
Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
Ellis WJ; Isaacs JT
Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
[TBL] [Abstract][Full Text] [Related]
3. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
Humphries JE; Isaacs JT
Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
5. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
Isaacs JT; Coffey DS
Cancer Res; 1981 Dec; 41(12 Pt 1):5070-5. PubMed ID: 7307008
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
7. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
Smolev JK; Heston WD; Scott WW; Coffey DS
Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
[TBL] [Abstract][Full Text] [Related]
9. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
Pollack A; Block NL; Stover BJ; Irvin GL
Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360
[TBL] [Abstract][Full Text] [Related]
10. Endocrine manipulation of the Dunning prostatic adenocarcinoma.
Shessel FS; Block NL; Stover B; Claflin A; Malinin TI; Politano VA
Invest Urol; 1980 May; 17(6):529-33. PubMed ID: 7372443
[TBL] [Abstract][Full Text] [Related]
11. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
Winneker RC; Parsons JA
Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344
[TBL] [Abstract][Full Text] [Related]
12. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Brändström A; Westin P; Bergh A; Cajander S; Damber JE
Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy: the benefits of postponed initiation.
Cockburn AG
Urology; 1984 Nov; 24(5 Suppl):24-6. PubMed ID: 6388093
[TBL] [Abstract][Full Text] [Related]
14. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
15. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1988; 260():101-10. PubMed ID: 2966402
[No Abstract] [Full Text] [Related]
16. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
17. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.
Isaacs JT; Wake N; Coffey DS; Sandberg AA
Cancer Res; 1982 Jun; 42(6):2353-71. PubMed ID: 7074614
[TBL] [Abstract][Full Text] [Related]
18. Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Isaacs JT; Weissman RM; Coffey DS; Scott WW
Prog Clin Biol Res; 1980; 37():311-23. PubMed ID: 7384091
[TBL] [Abstract][Full Text] [Related]
19. Experimental models for the study of prostatic adenocarcinoma.
Smolev JK; Coffey DS; Scott WW
J Urol; 1977 Jul; 118(1 Pt 2):216-20. PubMed ID: 875219
[TBL] [Abstract][Full Text] [Related]
20. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
